Following immunogenic challenge, infiltrating and dividing lymphocytes significantly increase lymph node (LN) cellularity leading to organ expansion 1,2 . Here we report that the physical elasticity of LNs is maintained in part by podoplanin (PDPN) signalling in stromal fibroblastic reticular cells (FRCs) and its modulation by CLEC-2 expressed on dendritic cells (DCs). We show that PDPN induces actomyosin contractility in FRCs via activation of RhoA/C and downstream Rho-kinase. Engagement by CLEC-2 causes PDPN clustering and rapidly uncouples PDPN from Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use
RhoA/C activation, relaxing the actomyosin cytoskeleton and permitting FRC stretching. Notably, administration of CLEC-2 protein to immunised mice augments LN expansion. In contrast, the latter is significantly constrained in mice selectively lacking CLEC-2 expression in DCs. Thus, the same DCs that initiate immunity by presenting antigens to T lymphocytes 3 also initiate remodeling of LNs by delivering CLEC-2 to FRCs. CLEC-2 modulation of PDPN signalling permits FRC network stretching and allows for the rapid LN expansion driven by lymphocyte influx and proliferation that is the critical hallmark of adaptive immunity.
LNs are meeting places for T lymphocytes and antigen presenting DCs 1,2 . T cell -DC interactions are supported by FRCs 4, 5 , a complex interconnected network that produces and ensheathes extracellular matrix components 6 that filter draining lymph 7 . FRC networks additionally provide physical routes for leucocyte traffic 1 , and chemoattractants for T cells and DCs 5 . Additionally, contact with FRCs promotes chemokinesis in DCs facilitating their migration within LNs 8 . This is partly due to cytoskeletal changes in DCs induced upon signalling by the C-type lectin receptor CLEC-2 when it is engaged by PDPN expressed on FRCs 8 . Here, we asked whether, in addition to promoting DC movement along FRCs, CLEC-2 might also work in reverse, modulating PDPN function and altering the properties of the FRC network.
To examine PDPN signalling in fibroblasts, wild-type (WT) PDPN tagged with CFP (PDPN-CFP) was over-expressed in NIH/3T3 cells, which express only low levels of the endogenous protein 8 . Within 30h of transfection, CFP was detectable at the plasma membrane where it co-localised with Cherry-tagged ezrin, consistent with reports of a direct interaction between the two proteins 9, 10 (Fig. 1a , Extended Data Video 1). Ezrin belongs to the family of closely related proteins, ezrin, radixin and moesin (ERM), which tether the actin cytoskeleton to the plasma membrane. We therefore examined localisation and phosphorylation of ERM proteins, along with myosin light chain (MLC), which mediates actin-dependent contraction, in PDPN-CFP overexpressing cells. In contrast to untransfected cells, PDPN-CFP + NIH/3T3 cells displayed pERM and pMLC accumulation at the cell cortex ( Fig. 1a) and often rounded up, features typical of contractile cells [11] [12] [13] [14] . A nonphosphorylatable ezrin T567A mutant formally demonstrated the key role of ERM phosphorylation in PDPN-driven cell contraction (Fig. 1b) .
To determine which pathways connected PDPN to cell contraction, a chemical screen was conducted, which revealed relaxation upon inhibition of RhoA/C, ROCK, or Myosin II (Extended data Fig. 1a, b) . Strikingly, treatment with soluble recombinant CLEC-2-Fc protein phenocopied RhoA/C and ROCK inhibition, almost completely reversing the contraction induced by PDPN-CFP (Fig. 1c) . The inhibition by CLEC-2 was rapid but transient ( Fig. 1c) and led to ezrin re-distribution from the plasma membrane to the cytoplasm (Fig. 1d) . To test this in FRCs expressing physiological levels of PDPN, we generated LN FRC lines (Extended Data Fig. 2 and Methods). Sub-lines stably expressing FRET biosensors reporting RhoA or Rac1 activity were exposed to CLEC-2-Fc-coated 10 μm beads. In agreement with the NIH/3T3 studies, RhoA activity was immediately and robustly reduced when CLEC-2-beads made contact with FRCs ( Fig. 1e and Extended Data Video 2). Sudden loss of RhoA activity was also evident from temporary loss of adhesion 15 (Extended Data Videos 2 and 3). In contrast, Rac1 activity gradually increased after exposure to CLEC-2 beads (Fig. 1e , and Extended Data Video 3), which was confirmed in longer-term experiments by pulldown of GTP-bound Rac1 (Fig 1f) . Higher Rac1-GTP levels, increased ARP2/3 + lamelipodial protrusions and tail retraction defects were also observed in FRCs when PDPN was stably depleted (PDPN KD FRCs; Fig. 1f and Extended data Fig. 3 ). To identify guanine-nucleotide exchange factors (GEFs) that may connect PDPN to activation of RhoA/C, we decreased expression of candidates using siRNA and found that PDPN-induced contractility primarily requires GEF-H1 in NIH/3T3 and FRCs (Extended data Fig. 1c, d ). We also looked for further changes in FRCs consistent with decreased RhoA/C activity and found that PDPN knockdown or engagement by CLEC-2 caused rapid dissolution of stress fibres (Fig. 1g , Extended Data Video 4, Extended data Figs. 3, 4) . Thus, PDPN in fibroblasts associates with ezrin and signals to promote RhoA/Cdependent actomyosin-driven contraction. This is alleviated by CLEC-2 engagement, causing uncoupling of PDPN from ezrin and a RhoA/C to Rac1 switch. We hypothesise that Rac1 activity is increased indirectly as a consequence of reduced RhoA/C activity 14, 16 .
The cytoplasmic tail of PDPN undergoes phosphorylation and ezrin recruitment requires basic residues surrounding serine 167 (S167) 10, 17 . We therefore tested whether phosphorylation of S167 controlled PDPN-induced contractility. Over-expression of PDPN (S167A) mutant failed to cause contraction in NIH/3T3 fibroblasts and occasionally caused collapse of the cytoskeleton, potentially by inhibiting activity of low levels of endogenous PDPN (Fig. 2a) . In contrast, a PDPN S167E phosphomimetic mutant induced contractility comparable to WT protein (Fig. 2a, b) . Inhibition of ROCK blocked contraction by both WT and S167E PDPN (Fig. 2b) , placing ROCK activity downstream of S167 phosphorylation. However, CLEC-2-Fc treatment, whilst inhibiting contraction induced by WT PDPN, had no effect on S167E PDPN (Fig. 2b) , suggesting that regulation of the phosphorylation status of S167 is one mechanism by which CLEC-2 uncouples PDPN from actomyosin contractility.
We considered how FRCs express high levels of endogenous PDPN yet, unlike transfected NIH/3T3 cells, do not display hypercontractility. As PDPN remained at the plasma membrane when engaged with CLEC-2 ( Fig. 1d) , we hypothesised that it partitions between active and inactive pools, the latter being maintained by binding to an inhibitory partner such as CD44 18, 19 . FRCs express high levels of both PDPN and CD44 4 and knockdown of PDPN led to a concordant reduction of CD44 (Fig. 2c) , suggesting an interaction. NIH/3T3 express low levels of CD44, perhaps accounting for their susceptibility to contract following PDPN overexpression. Consistent with that notion, co-transfection of CD44 and PDPN into NIH/3T3 fibroblasts markedly inhibited contraction (Fig. 2d) .
CD44 resides within cholesterol-rich lipid rafts 19 and we tested whether CLEC-2 induces PDPN redistribution to such rafts. In steady state FRCs, PDPN and lipid rafts were found in small, partial colocalised clusters (Fig. 2e) , as described in epithelial cells 20 . CLEC-2-Fc treatment induced formation of larger clusters in which PDPN and lipid rafts were more often colocalised (Fig. 2e) . Notably, depletion of cholesterol from FRC membranes with methyl-β-cyclodextrin (MβCD) increased contractility, which was prevented by PDPN knockdown (Fig. 2f) . CLEC-2 no longer inhibited PDPN-induced contraction in NIH/3T3 pre-treated with MβCD (Fig. 2g) . Together, these data support the notion that CLEC-2 sequesters PDPN within lipid rafts, where increased interaction with CD44 prevents signalling to RhoA/C. Interestingly, CD44 can itself also drive contractility when excluded from lipid rafts (data not shown) suggesting a mutually inhibitory interaction with PDPN.
To explore the biological significance of PDPN/CLEC-2 interactions for FRC function, we examined cell behaviour in 3D collagen gels. Notably, FRCs reorganised the gel matrix to occupy a smaller volume and this was inhibited by CLEC-2 treatment or PDPN knockdown (Fig. 3a) . Furthermore, CLEC-2 treatment or PDPN knockdown caused marked elongation of FRCs in 3D culture (Fig. 3b, Extended data Fig. 5 ). To determine the relevance of FRC stretching for LN dynamics, we investigated FRC network changes following induction of inflammation in vivo, which leads to upregulation of CLEC-2 by both LN resident and migratory DCs 8, 21 . We first examined the cellular composition of draining LNs after subcutaneous immunisation of mice with ovalbumin (OVA) in complete Freund's adjuvant (CFA). During the afferent phase (days 0-6), T and B cell numbers increased rapidly and total LN cellularity augmented 2-3 fold (Extended data Fig. 6 ). However, numbers of FRCs (CD45 − PDPN + CD31 − ) remained constant until day 6 (Fig. 3c ). This lag in FRC proliferation has been previously observed 22 although the kinetics likely depend on the type and strength of the inflammatory stimulus. In contrast, blood endothelial cells (BECs; CD45 − PDPN − CD31 + ), a distinct LN stromal population, increased in number from the earliest timepoint (Extended data Fig. 6 ).
If FRCs do not proliferate during early stages of acute inflammation, then to accommodate increased LN size the FRC network needs to 'stretch' to avoid disruption 22 . Consistent with that, the mean forward scatter of LN FRCs, an indication of cell size, increased after immunisation (Fig. 3d) 22 despite no loss of integrity of the FRC network (Fig. 3e) . A gap analysis algorithm 23 revealed significantly larger spaces between the reticular network branches after immunisation, consistent with FRC stretching (Fig. f) . In a complementary approach, we utilised PDGRFaKI-H2B-GFP mice (Extended data Fig. 7 ) and calculated the spacing between FRC nuclei (GFP + ) using automated morphometric analysis software, which confirmed that FRCs spread further apart after immunisation (Fig. 3g) . Together, these data indicate that FRCs expand and that the pre-existing FRC network enlarges in response to acute inflammation such as following immunisation.
The profound cytoskeletal changes in FRCs following CLEC-2 binding in vitro, suggested that inhibition of PDPN-induced contractility by CLEC-2 + DCs might aid FRC network enlargement in vivo. Consistent with this, LN influx of immigrant DC (CD45 + , CD11c + , MHCII hi ) bearing high CLEC-2 levels 8 peaked at day 2 post OVA/CFA immunisation (Fig.  3c) . We therefore examined LN architecture and expansion in CD11cCre × Clec1b loxP/loxP mice (CD11c ΔCLEC-2 ). These mice display selective ablation of CLEC-2 in CD11c + cells (Extended data Fig. 8 ), the majority of which within the T cell zone are DCs. Interestingly, in >24 week old CD11c ΔCLEC-2 mice, steady state LN size was significantly reduced compared to controls (Fig 4a) , which was not the case in younger mice ( Fig. 4b ; nondraining LN). However, following immunisation, expansion of draining LNs was attenuated and spaces within the FRC network were smaller in young CD11c ΔCLEC-2 mice compared to controls (Fig. 4b, c) . Finally, LNs of CD11c ΔCLEC-2 mice remained more rigid and less deformable than controls following immunisation (Fig 4d) .
Attenuated expansion of LNs in CD11c ΔCLEC-2 mice could be due to reduced numbers of immigrating DCs, reducing antigen availability and limiting T cell expansion. However, similar results were obtained upon administration of incomplete Freund's adjuvant without OVA or mycobacterial antigens (data not shown). Moreover, treatment by subcutaneous injection of recombinant CLEC-2-Fc protein but not a control Fc reagent (data not shown) following CFA/OVA immunisation markedly augmented LN expansion (Fig. 4e ) and, importantly, completely rescued defects in LN expansion in CD11c ΔCLEC-2 mice (Fig 4e) . The latter result indicates that diminished CLEC-2 provision rather than a dearth of immigrant antigen-presenting DCs limits LN expansion in CD11c ΔCLEC-2 mice. In sum, these data suggest that CLEC-2 delivery by DCs is required for maintaining FRC network architecture in vivo and is permissive for acute increases in LN size driven by cell influx provoked by local inflammation.
LNs are dynamic structures that must rapidly expand to accommodate leucocyte recruitment and proliferation. Given that LNs can expand 10-fold during adaptive immune responses while maintaining integrity, stromal components must by necessity proliferate 22, 24 . However, in early phases of adaptive immune responses or in response to acute inflammation, FRC proliferation is insufficient to account for lymph node expansion ( Fig.  3b and 22 ). Here, we show that early LN expansion is permitted by FRC network relaxation, induced by increased availability of CLEC-2 hi DCs. We previously reported that CLEC-2 engagement by PDPN promotes DC migration along the FRC network 8 . Our data now show that PDPN is not simply a ligand for CLEC-2 but that it also reverse signals into FRCs to control actomyosin contractility. Our results suggest that a function of endogenous PDPN on FRCs is to cause stromal network contraction and create physical tension in LNs. This is offset by constant contact between FRCs and CLEC2 + resident DCs, balancing contractility and controling LN cellularity. The influx of additional CLEC-2 hi DCs, combined with the upregulation of CLEC-2 on resident DCs during acute inflammation 8 , increases inhibition of PDPN, allowing the FRC network to stretch. We predict that this same mechanism can promote LN reduction as the short wave of increased CLEC-2 availability ends and PDPN activity returns. Whether the underlying collagen network is similarly elastic and to what extent acts to limit or promote LN expansion is as-yet unaddressed. Interestingly, CLEC-2 is not sufficient for LN expansion as administration of CLEC-2-Fc in the absence of inflammation did not affect LN size. Rather, CLEC-2 inhibition of PDPN is permissive for stretching and the influx of leucocytes via the HEV and afferent lymph likely provides the force for expansion. It is interesting to speculate that the stretching mechanism described in this study may also help initiate subsequent FRC proliferation given the emerging connections between tension and cell cycle regulation 25 .
Methods

Mice
Experiments were performed in accordance with national and institutional guidelines for animal care and approved by the Institutional Animal Ethics Committee Review Board, Cancer Research UK and the UK Home Office. Wild-type C57BL/6J mice were purchased from Charles River Laboratories (Wilmington, MA). PDGFRaKI-H2B-GFP mice (B6.129S4-Pdgfratm11(EGFP)Sor/J) were purchased from Jackson laboratories. To generate Clec1b floxed mice on a C57BL/6 background, C57BL/6 mouse clec1b genomic regions were cloned into a pFloxRI+TK targeting vector from the BAC clone R248K14 using the Red/Et recombination of Quick and Easy BAC modification kit (Gene Bridges, Dresden -Germany). Primers used were:
Upper case represent regions homologous to clec1b regions and lower case represent regions homologous to pFloxRI+TK vector. PCR was performed using Pwo DNA polymerase (Roche) following the manufacturer's instructions.
The 5′ loxP site was introduced in the intronic region between exon 1 and exon 2 by insertion of the loxP-pgk-gb2-NEO-loxP cassette (Gene Bridges, Dresden -Germany) using the following primers: Upper case represent regions homologous to clec1b regions and lower case represent regions homologous to loxP-pgk-gb2-NEO-loxP cassette. PCR was performed using Pwo DNA polymerase (Roche) following the manufacturer's instructions.
The vector was then transformed into CRE-expressing E. coli EL350 (kind gift from Axel Behrens) leading to recombination of the cassette and leaving a single loxP site.
Next, the FRT-pgk-gb2-NEO-FRT-loxP cassette was introduced into the intronic region between exon 4 and exon 5 using the following primers: Fw Rb2 Screening for homologous recombination in ES and mice was done by PCR using primers inside the FRT-pgk-gb2-NEO-FRT-loxP and outside the homology arm:
C1b Gen Rv -agaccctgagaaggctgga NEO 3′ sense -gctcccgattcgcagcgcatc Deletion of the NEO cassette was performed by crossing Clec1b-targeted mice with βActin-Flp (B6.Cg-Tg(ACTFLPe)9205Dym), and thereafter generating Clec1b lox/lox by interbreeding and screening for deletion of the NEO cassette using the following primers:
Seq FRT Fw (cctggtaaggagggtcccat) and Seq FRT Rv (atgagtctgctagggatgct).
Generation of CD11cΔCLEC-2 was achieved by crossing Clec1b lox/lox with CD11c-Cre mice (B6.Cg-Tg(Itgax-cre)1.1Reiz; kind gift from Boris Reizis). Both males and females were used for in vivo experiments and were aged 8-12 weeks unless otherwise stated in figures. Cre negative littermates were used as controls in all experiments.
qPCR analysis of Clec1b mRNA
CD11c+ cells from day 9 cultures of bone marrow in GM-CSF (BMDC) and treated with LPS for 6h or from spleens were enriched by MACS using CD11c beads (Miltenyi). RNA was extracted using an RNeasy mini kit (Qiagen) and cDNA generated using Superscript II reverse transcriptase (Invitrogen). qPCR was carried out using Sybr Green comparing Clec1b expression to GAPDH in each sample. Primers for Clec1b: Forward -TTTGAGCACAAGTGCAGCCCC, Reverse -AAGCAGTTGGTCCACTCTTG.
Constructs
PDPN-CFP was as previously described 8 . RhoA and Rac-1 FRET biosensors were kindly provided by Michiyuki Matsuda. GFP-MLC was as previously described 12 . PDPN WT and mutants S167A and S167E were cloned into pcDNA3.1-V5-His by PCR using EcoR1 and Not-1 restriction sites.
Cell lines
NIH/3T3 fibroblasts were cultured in Dulbecco's modified Eagle's medium (DMEM) + glucose (Life Technologies, Invitrogen, CA, USA) with 10% fetal bovine serum (FBS) and penicillin and streptomycin (PS). Cells were incubated and maintained at 37°C in 5% CO 2 .
Mouse LN FRC lines were generated by first digesting skin-draining lymph nodes from C57BL/6 mice and then culturing adherent stromal cells as previously reported 8 
Over-expression studies
NIH/3T3 cells were plated at a density of 50,000 cells/ml in a glass-bottomed 24 well plate (MatTek, MA, USA) the day before transfection with plasmids encoding GFP, PDPN-CFP or PDPN-V5-his using Effectene transfection reagent (Qiagen, Hilden, Germany) as per supplier's instructions. After 24 hours, cells were treated with chemical inhibitors at the concentrations indicated (see Extended data Fig. 1b ) for 6 hours before fixation. CLEC-2-Fc was added at 10 μg/ml for the time indicated in figures before fixation. In cotransfection experiments, plasmids encoding PDPN-CFP and ezrin-Cherry or PDPN-V5-his and CD44-GFP were added in equal amounts to the transfection mix. The cells were analysed by fluorescence microscope (20×, Nikon Eclipse Te2000-S, Tokyo, Japan) and contraction status scored manually. Cells were grouped into either contracted, partially contracted, spread or collapsed, depending on their morphology. High-resolution images were taken using a confocal microscope (Zeiss 710 using a 20×/0.8NA objective).
Immunofluorescence staining
Cells were fixed with 4% paraformaldehyde (PFA) in PBS for 10 minutes before permeabilisation in PBS containing 0.2% Triton-X for 10 minutes at room temperature. The cells were stained with DAPI (Sigma, d9542, MO, USA) to reveal DNA in cell nuclei and TRITC-phalloidin (Sigma, p1951, MO, USA) to reveal F-actin in 3% bovine serum albumin with PBS + 0.1% Tween-20. Cells were stained using anti-pMLC (S19) (Cell signaling technology #3675) or anti-pERM antibody (Cell signaling technology #3141) followed by appropriate Alexafluor-conjugated secondary antibodies (Invitrogen). PDPN-V5 was stained using anti-V5 FITC-conjugated antibody (Invitrogen R963-25). ARP2/3 was stained using Anti-p34-Arc/ARPC2 antibody (07-227 Millipore).
Lipid raft colocalisation analysis
Lipid raft labelling was carried out on ice on unfixed cells according to manufacturer's instructions (Vybrant lipid raft labelling kit 555, Invitrogen). Cells were then fixed in 4% paraformaldehyde before staining for PDPN (8.1.1 AF660-conjugated (eBioscience 50-5381-80). Confocal immunofluorescence images (63×/1.4NA oil immersion objective) of FRCs plated on glass either untreated or treated with 10 μg/ml CLEC-2-Fc for 30 minutes prior to staining were analysed using Zen image analysis software (Zeiss). Correlation coefficient R was calculated based on pixel intensity.
CLEC-2-Fc treatment in vitro
Generation of CLEC-2-Fc was as previously described 8 . Soluble CLEC-2 was used at 10 μg/ml diluted in cell culture medium. For CLEC-2-beads, 10 μm protein A-coated microspheres (Bangs laboratories) were incubated with 100 μg/ml CLEC-2-Fc diluted in PBS for 1 hour at 4°C then washed with cell culture medium. CLEC-2-Fc or CLEC-2-beads were added for the time indicated in the figures before fixation.
Lymph node expansion in vivo
Mice were immunised with 100 μl of an emulsion of OVA in CFA (100 μg OVA per mouse) or PBS in IFA subcutaneously in the right flank. Draining inguinal lymph nodes were taken for analysis at the indicated days post-immunisation; left-side non-draining lymph nodes were taken for comparison. Where mice were treated with CLEC-2-Fc, they received 10 μl (1 μg in PBS) subcutaneously adjacent to site of immunisation on days 1 and 3. Lymph nodes were first weighed, then digested as previously described 27 . Cells were counted and stained for flow cytometry analysis. Alternatively, intact lymph nodes were fixed in 10% formalin for immunohistochemistry analysis.
Lymph node deformation assay
Draining and non-draining inguinal lymph nodes were taken from CD11c ΔCLEC-2 mice and littermate controls on day 5 following CFA immunisation. Lymph nodes were placed on the contact points of a digimatic thickness gauge (Mitutoyo, USA) and subjected to 1.4N of applied force. Deformability was calculated as follows: Deformability = 1 -(LN size under 1.4N/LN size before force was applied). Each LN was measured twice and the results averaged. 
Flow cytometry
Cells isolated from
Immunohistochemistry
Tissue sections 4 μm thick were cut at 3 levels (with 150μm between the levels) from formalin-fixed paraffin-embedded lymph nodes. These sections were then stained using the Vector ABC elite detection system (PK6100 1:250,Vector laboratories, UK). Slides were first incubated with a primary antibody for 1 hour (anti-GFP: AB6673 1:350, Abcam, anti-PDPN: DM3501, Acris), followed by incubation with biotinylated-labelled secondary antibody (1:250, Vector laboratories, UK) for 45 min. ABC complex was then applied for 30 minutes and staining was completed by 3 min incubation with DAB and chromogen (SK 4100 Vector laboratories, UK). Slides were counterstained with hematoxylin and mounted. ER-TR7 staining was conducted on 10 μm thick frozen LN sections (Santa Cruz sc-73355-AF488)
Gap analysis
Quantification of gap sizes was carried out in MATLAB. PDPN signal was isolated and converted to grayscale. The images were thresholded, background subtracted, small objects removed, then converted to binary images using ImageJ software. A circle-fitting algorithm was applied whereby, in each step, the largest circle that could fit in the gaps and that did not overlap with other fitted circles was recorded. The distribution of radii of circles that fill the image was then weighted according to area such that larger circles had a proportionally greater weighting than smaller circles. The plot of distribution of radii was smoothed to transform the data from a discrete pixel size distribution to a continuous micron size distribution. Raw data were analysed using Fisher's exact test (p = 4.194e-09) to determine differences in circles with radius >15 μm. Each analysis was performed on images of the FRC network from >8 individual mice per group. No images were excluded from the analysis and all data were combined and are represented in the graphs shown (16 images per group). MATLAB script is available upon request.
Automated Morphometric analysis
The slides were digitised with a commercial image analysis system (Ariol; Leica Biosystems). The program was trained to recognise GFP+ stained nuclei by size, shape and staining intensity. T cell areas were identified by density of hematoxylin staining and traced out manually on each lymph node in the scan. Automated analysis then counted the total number of GFP+ nuclei in each T cell area, (24 areas analysed per group). Area/FRC nuclei were compared using Mann Whitney U test.
Rac1GTP pulldown assay
FRC cell lines either treated with CLEC-2-Fc for 30 minutes or stably depleted of PDPN (shRNA) were subjected to Rac1 pulldown and analysis as per manufacturer's instructions (kit 16118 Pierce). Rac-1 levels in pulldowns and whole lysate were compared by Western blot.
3D cell culture and gel contraction assay
Control or PDPN KD FRCs were seeded at 10,000 per well in 150 μl collagen/matrigel matrix 8, 26, 28 . Gels were set at 37°C for 30 minutes then covered with cell culture medium.
In some wells, the following were added to both the gel mix and medium: 10 μg/ml CLEC-2-Fc, 10 μM ROCK inhibitor (Y27632) or 10 μg/ml anti-PDPN antibody (R&D, AF3244). Contraction of the gel at day 3 was quantified as the ratio of contracted gel/ original area and plotted relative to control. Gels were stained with TRITC-labelled phalloidin and DAPI for maximum length analysis (Imaris). The furthest points of each individual cell were measured in x,y,z coordinates and vectors calculated for comparison (Extended data figure 5 ).
Statistics
Sample size for in vivo experiments was determined by litter size as littermate controls were used in all comparisons. For in vitro experiments, all cells within the sample were scored and none excluded and experiments were repeated at least once to ensure reproducibility and adequate statistical power. Category data from over-expression studies was analysed using Fisher's exact test (R software). Changes to contraction and morphology were analysed using Mann Whitney-U tests. Analysis of cell populations during a time course of immunisation was conducted with one-way ANOVA and followed by Kruskall-Wallis multiple comparisons test. Comparison of LN size and cellularity between control and CD11c ΔCLEC-2 across different treatment groups was analysed using 2-way ANOVA followed by multiple comparisons test between treatments and genotypes. Appropriate statistical tests were chosen for the data set following advice from a mathematician (R.P.J.). Chemical screen for cell contraction inhibitors was scored by an independent observer (A.F.) who was unbiased as to the predicted results. 
Extended Data Videos
Refer to Web version on PubMed Central for supplementary material. 
